Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the ...

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...

Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly ...

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of ...

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical ...

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...